Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
66 hedge funds and large institutions have $168M invested in Catalyst Pharmaceutical in 2015 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
107% more capital invested
Capital invested by funds: $81.3M → $168M (+$87.1M)
58% more call options, than puts
Call options by funds: $128K | Put options by funds: $81K
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
32% more funds holding
Funds holding: 50 → 66 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$17.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.1M |
| 3 |
BC
Broadfin Capital
New York
|
+$6.07M |
| 4 |
PA
Perceptive Advisors
New York
|
+$4.33M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.9M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$2.46M |
| 3 |
VAM
Visium Asset Management
New York
|
-$2.21M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$1.64M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$743K |
CPRX Hedge Fund Activity: Q1 2015 in Review
66 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2015, worth a combined $168M — up 107% from $81.3M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CPRX positions and 8 closed out — a net gain of 16 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $17.5M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.9M sold.
- 66 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2015, up from 50 in Q4 2014.
- Funds reported $168M of Catalyst Pharmaceutical stock for Q1 2015, up 107% quarter-over-quarter.
- 24 funds opened new Catalyst Pharmaceutical positions in Q1 2015 and 8 closed out, a net change of +16 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2015 was Consonance Capital Management, an estimated $17.5M added.
- The largest Catalyst Pharmaceutical seller in Q1 2015 was Opaleye Management, an estimated $2.9M sold.
Based on aggregated 13F filings for Q1 2015.